FDA clears Exatech’s Vantage Total Ankle — 5 highlights

The FDA has cleared Exatech’s Vantage Total Ankle device.

Advertisement

Here are five highlights:

 

1. The Vantage Total Ankle is used to treat patients who suffer from arthritis in the ankle.

 

2. It is the latest product in Exatech’s extremities line, and it’s first in the company’s foot and ankle portfolio.

 

3. The Vantage Total Ankle allows for both stability and mobility in total ankle arthroplasty. The system incorporates the press-fit bone cage design used in the Equinoxe shoulder system, developed to allow for initial and long-term fixation.

 

4. Exatech plans to initiate targeted clinical evaluation of the Vantage Total Ankle this summer, with full-scale release scheduled for the first quarter of 2017.

 

5. Based in Gainesville, Fla., Exatech develops and markets orthopedic implant devices, related surgical instruments and biologic materials and services to hospitals and physicians.

 

More articles on devices and implants:
Zimmer Biomet, Cayenne Medical enter acquisition agreement — 5 insights
Startup pushes Google Glass deeper into healthcare — 3 insights
Medacta to host 8th annual symposium on spine, knee & hip advancements: 4 things to know

At the Becker's 23rd Annual Spine, Orthopedic and Pain Management-Driven ASC + The Future of Spine Conference, taking place June 11-13 in Chicago, spine surgeons, orthopedic leaders and ASC executives will come together to explore minimally invasive techniques, ASC growth strategies and innovations shaping the future of outpatient spine care. Apply for complimentary registration now.

Advertisement

Next Up in Spinal Tech

  • From new technology acquisitions to regulatory clearances to leadership changes, here are 20 developments and updates from the biggest players…

  • SurGenTec’s ION-C earned FDA 510(k) clearance for ION-C navigation instruments with the ION-C posterior cervical facet fixation implant, according to…

  • VB Spine has made big pushes into the spine medtech space so far in 2026, including global expansions. Six headlines…

Advertisement

Comments are closed.